Home    Back

 236. Pseudohypoparathyroidism
 [ 4 clinical trials,    3 drugs（DrugBank: 2 drugs),    20 target genes / 28 target pathways ] 

Searched query = "Pseudohypoparathyroidism"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03718403April 10, 20195 November 2018Effect of Theophylline in PseudohypoparathyroidismEffect of Theophylline in PseudohypoparathyroidismPHP Ia;PHP IB;Php1CDrug: TheophyllineMassachusetts General HospitalNot recruiting5 Years21 YearsAll40Phase 4
2NCT03029429September 1, 201815 July 2019Theophylline Treatment for PseudohypoparathyroidismPhase 2 Study of Theophylline Treatment for PseudohypoparathyroidismPseudohypoparathyroidism;Albright Hereditary OsteodystrophyDrug: Theophylline;Drug: PlacebosVanderbilt University Medical CenterHarvard UniversityRecruiting2 Years25 YearsAll34Phase 2United States
3NCT02463409June 201516 December 2017Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1aPseudohypoparathyroidism Type 1a;Albright Hereditary OsteodystrophyDrug: TheophyllineVanderbilt University Medical CenterMassachusetts General HospitalNot recruiting10 Years21 YearsAll6Phase 2United States
4NCT00497484February 199519 February 2015Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Pseudohypoparathyroidism;Growth Hormone Deficiency, DwarfismDrug: recombinant human somatotropinUniversity of MilanEli Lilly and CompanyNot recruiting1 Year18 YearsBothN/AItaly